Hodgkins Lymphoma Market 2024: Opportunity Analysis and Forecasts

"The Latest Research Report OpportunityAnalyzer: Hodgkins Lymphoma (HL) - Opportunity Analysis and Forecasts to 2024 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"

About Hodgkins Lymphoma Market

Hodgkins lymphoma (HL), or Hodgkins disease, is a malignancy which involves the lymph nodes and the lymphatic system. HL is a relatively rare type of cancer, accounting for 12% of all lymphomas and 0.6% of all new cancer cases, but overall prognosis is very good. However, treatment options for those patients who have failed first-line treatment are very few, and a significant unmet medical need remains in those patients. GlobalData estimated the HL market in the 7MM was valued at $316m in 2014. The HL market will increase approximately four-fold over the forecast period, reaching $1.4 billion by 2024 at a CAGR of 16%. This growth will be driven by label extensions for Adcetris (brentuximab vedotin), which is poised to enter earlier lines of HL therapy, as well as the approval and uptake of premium-priced products, such as the immune checkpoint inhibitors, Opdivo (nivolumab) and Keytruda (pembrolizumab). By the end of the forecast period, GlobalData expects Adcetris to retain and extend its lead as the HL market front-runner, with Opdivo and Keytruda making up a significant amount of the market. GlobalData anticipates that pipeline agents will have to show an efficacy advantage over currently used and inexpensive standard of care therapies. The challenge for new entrants in the HL market is to meet the high unmet need of relapsed or refractory (R/R) HL patients, reduce the long-term toxic side effects of current treatments, and improve overall survival.

Highlights

Key Questions Answered

- Over the last forty years, only one targeted therapy has been approved for the treatment of HL - Adcetris. The HL space is now filled with excitement because Adcetris label extensions and approval of the first anti-PD-1 therapies are expected to change the treatment landscape. What will be the impact of these newly approved drugs on HL sales?

Get Sample copy of this Report @ https://www.marketresearchreports.biz/sample/sample/705200

- With the success of molecular-targeted therapies, including immune checkpoint inhibitors, across the oncology therapy area, what R&D strategies are being leveraged by companies to remain competitive in the HL space?
- The survival of R/R HL patients remains poor, especially for those who fail transplant therapies. Therefore, there are considerably high unmet needs within this indication. What are the main unmet needs remaining in this space? Will the drugs under development fulfil the unmet needs of the HL market?

Key Findings

- One of the main drivers in the expansion of the HL market will be the label extensions of Adcetris in earlier lines of HL therapy, which will include the post-transplantation consolidation setting, as well as newly diagnosed advanced stage patients. The premium-priced anti-PD1-therapies, Opdivo and Keytruda, will also launch and be used in the treatment of the R/R HL population. These drugs are poised to partially meet the remaining unmet medical need of these hard-to-treat patients.
- Another driver of market growth will be the few players in the HL space; therefore, there is ample room for new market entrants. A major driver will also be an increase in HL incidence due to a growing population. This will lead to an overall increase of the number of drug-treatable HL patients, and market size.
- Companies are focusing on the development of therapies targeting the R/R HL population, hoping to expedite the route to market for their pipeline products, and improving the complete remission rate and duration of remission of these patients.
- One of the largest unmet needs is that of the newly diagnosed advanced stage HL population. Other unmet needs include the high proportion of patients failing transplant therapies and the toxicity of second-line treatment options.

View Report @ https://www.marketresearchreports.biz/reports/705200/opportunityanalyzer-hodgkins-lymphoma-hl-opportunity-analysis-and-forecasts-to-2024-market-research-reports

Scope

- Overview of HL, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
- Top-line HL therapeutics market revenue from 2014-2024. Average cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the HL market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.
- Analysis of the current and future market competition in the global HL market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Send An Enquiry Request @ https://www.marketresearchreports.biz/sample/enquiry/705200

Reasons to buy

The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global HL market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global HL market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents 12
1.1 List of Tables 17
1.2 List of Figures 21
2 Introduction 22
2.1 Catalyst 22
2.2 Related Reports 23
2.3 Upcoming Related Reports 23
3 Disease Overview 24
3.1 Etiology and Pathophysiology 26
3.1.1 Etiology 26
3.1.2 Pathophysiology 28
3.2 Symptoms 33
3.3 Diagnosis 34
3.4 Clinical Staging and Prognostic Factors 34
4 Epidemiology 37
4.1 Disease Background 37
4.2 Risk Factors and Comorbidities 38
4.3 Global Trends 39
4.3.1 Incidence 39
4.3.2 Survival Rates for HL - 7MM 42
4.4 Forecast Methodology 43
4.4.1 Sources Used 46
4.4.2 Sources Not Used 47
4.4.3 Forecast Assumptions and Methods, HL Diagnosed Incident Cases 48
4.4.4 Forecast Assumptions and Methods, HL Five-Year Diagnosed Prevalent Cases 49
4.4.5 Forecast Assumptions and Methods, HL Diagnosed Incident Cases, Clinical Stages at Diagnosis 49
4.4.6 Forecast Assumptions and Methods, HL Diagnosed Incident Cases, Cellular Types 50
4.5 Epidemiological Forecast for HL (2014-2024) 51
4.5.1 Diagnosed Incident Cases of HL 51
4.5.2 Age-Specific Diagnosed Incident Cases of HL 52
4.5.3 Sex-Specific Diagnosed Incident Cases of HL 54
4.5.4 Age-Standardized Diagnosed Incidence of HL 56
4.5.5 Diagnosed Incident Cases of HL by Clinical Stage at Diagnosis 58
4.5.6 Diagnosed Incident Cases of HL by Cellular Types 59
4.5.7 Five-Year Diagnosed Prevalent Cases of HL 60
4.6 Discussion 61
4.6.1 Epidemiological Forecast Insight 61
4.6.2 Limitations of the Analysis 62
4.6.3 Strengths of the Analysis 62
5 Current Treatment Options 64
5.1 Overview 64
5.1.1 Treatment of Classical HL 65
5.1.2 Treatment of NLPHL 68
5.1.3 Treatment of Children and Pregnant HL Patients 68
5.1.4 Marketed Agents for the Treatment of HL 69
5.2 Product Profiles 70
5.2.1 Adcetris (brentuximab vedotin) 70
6 Unmet Needs Assessment and Opportunity Analysis 89
6.1 Unmet Needs Analysis 89
6.1.1 Overview 89
6.1.2 Low Cure Rate in Newly Diagnosed Advanced Unfavorable-Stage Patients 90
6.1.3 Only Half of Relapse/Refractory Patients Are Cured by ASCT 91
6.1.4 Toxic Second-Line Chemotherapy 92
6.1.5 Long-Term Toxicity Associated With Radiotherapy 93
6.1.6 Current Treatment Is Less Effective in Older HL Patients 94
6.1.7 Underuse of Prognostic Factors for Treatment Planning in the Front-Line and Relapse/Refractory Settings 95
6.1.8 Prohibitively High Cost of Therapy 96
6.1.9 Lack of Patients to Participate in Clinical Trials 97
6.2 Opportunity Analysis 98
6.2.1 Overview 98
6.2.2 Less Toxic and More Efficacious Front-Line Therapies Will Increase Acceptance for Premium Price 98
6.2.3 Therapies and Strategies That Improve Cure Rates in the Relapse/Refractory Setting 100
6.2.4 New Therapies Adapted for the Treatment of Older HL Patients 102
6.2.5 Pharmacological Therapies That Can Replace Radiation Therapy 103
6.2.6 Reducing Treatment Cost to Enhance Overall Treatment Rate and Drug Uptake 104

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: sales@marketresearchreports.biz

This release was published on openPR.